Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence

References

• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm (Vienna). 2004;111(2):201–216. doi:10.1007/s00702-003-0102-y
   PubMed Web of Science ®Google Scholar
• De Leonibus E, Verheij MM, Mele A, Cools A. Distinct kinds of novelty processing differentially increase extracellular dopamine in different brain regions. Eur J Neurosci. 2006;23(5):1332–1340. doi:10.1111/j.1460-9568.2006.04658.x
   Web of Science ®Google Scholar
• De Leonibus E, Pascucci T, Lopez S, Oliverio A, Amalric M, Mele A. Spatial deficits in a mouse model of Parkinson disease. Psychopharmacology (Berl). 2007;194(4):517–525. doi:10.1007/s00213-007-0862-4
   Web of Science ®Google Scholar
• Pagonabarraga J, Kulisevsky J. Apathy in Parkinson’s disease. Int Rev Neurobiol. 2017;133:657–678.
   PubMed Web of Science ®Google Scholar
• Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia. 2016;6:123–148.
   PubMedGoogle Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med. 1969;280(7):337–345. doi:10.1056/NEJM196902132800701
   PubMed Web of Science ®Google Scholar
• Foley P, The L-DOPA story revisited. Further surprises to be expected? J Neural Transm Suppl. 2000;(60):1–20. doi:10.1007/978-3-7091-6301-6_1
   Google Scholar
• Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord. 1998;4(2):59–60. doi:10.1016/S1353-8020(98)00013-3
   PubMedGoogle Scholar
• Müller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2020;16(5):403–414. doi:10.1080/17425255.2020.1750596
   PubMed Web of Science ®Google Scholar
• Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson’s disease. Mov Disord. 2001;16(6):1041–1047. doi:10.1002/mds.1203
   Web of Science ®Google Scholar
• Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006;29(2):61–67. doi:10.1097/00002826-200603000-00001
   PubMed Web of Science ®Google Scholar
• Müller T. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clin Neuropharmacol. 2013;36(3):84–91. doi:10.1097/WNF.0b013e31828f3385
   PubMed Web of Science ®Google Scholar
• Schuurkes JA, Van Nueten JM. Is dopamine an inhibitory modulator of gastrointestinal motility? Scand J Gastroenterol Suppl. 1981;67:33–36.
   Google Scholar
• Muhlack S, Herrmann L, Salmen S, Müller T. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm. 2014;121(11):1357–1366. doi:10.1007/s00702-014-1213-3
   PubMed Web of Science ®Google Scholar
• Riederer P, Müller T. Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects. J Neural Transm (Vienna). 2018;125(11):1751–1757. doi:10.1007/s00702-018-1876-2
   PubMed Web of Science ®Google Scholar
• Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6(2):141–150. doi:10.1111/j.1468-1331.1999.tb00007.x
   PubMed Web of Science ®Google Scholar
• Ramot Y, Nyska A, Maronpot RR, et al. Ninety-day local tolerability and toxicity study of ND0612, a novel formulation of levodopa/carbidopa, administered by subcutaneous continuous infusion in minipigs. Toxicol Pathol. 2017;45(6):764–773. doi:10.1177/0192623317729891
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Müller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm (Vienna). 2012;119(3):369–372. doi:10.1007/s00702-011-0689-3
   PubMed Web of Science ®Google Scholar
• Müller T, Laar TV, Cornblath DR. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord. 2013;19(5):501–507. doi:10.1016/j.parkreldis.2013.02.006
   PubMed Web of Science ®Google Scholar
• Billings JL, Gordon SL, Rawling T, et al. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson’s disease. J Neurochem. 2019;150(1):88–106. doi:10.1111/jnc.14676
   Web of Science ®Google Scholar
• Sian-Hulsmann J, Riederer P. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s disease. J Neural Transm (Vienna). 2020;127(5):749–754. doi:10.1007/s00702-020-02192-0
   Web of Science ®Google Scholar
• Sun Y, Pham AN, Hider RC, Zheng H, Waite TD. Effectiveness of the iron chelator CN128 in mitigating the formation of dopamine oxidation products associated with the progression of Parkinson’s disease. ACS Chem Neurosci. 2020;11(21):3646–3657. doi:10.1021/acschemneuro.0c00557
   Web of Science ®Google Scholar
• Zhou ZD, Lan YH, Tan EK, Lim TM. Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration. Free Radic Biol Med. 2010;49(12):1856–1871. doi:10.1016/j.freeradbiomed.2010.09.010
   Web of Science ®Google Scholar
• Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson’s disease. Neurology. 1999;52(1):120–125. doi:10.1212/WNL.52.1.120
   PubMed Web of Science ®Google Scholar
• Fletcher EA, Redfern PH. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J Pharm Pharmacol. 1970;22(12):957–959. doi:10.1111/j.2042-7158.1970.tb08486.x
   Web of Science ®Google Scholar
• Heimans RL, Rand MJ, Fennessy MR. Effects of amantadine on uptake and release of dopamine by a particulate fraction of rat basal ganglia. J Pharm Pharmacol. 1972;24(11):875–879. doi:10.1111/j.2042-7158.1972.tb08906.x
   Web of Science ®Google Scholar
• Schendzielorz N, Oinas JP, Myohanen TT, Reenila I, Raasmaja A, Mannisto PT. Catechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain. PLoS One. 2013;8(4):e61392. doi:10.1371/journal.pone.0061392
   Web of Science ®Google Scholar
• Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther. 2002;303(3):952–958. doi:10.1124/jpet.102.039743
   Web of Science ®Google Scholar
• Giordano N, Iemolo A, Mancini M, et al. Motor learning and metaplasticity in striatal neurons: relevance for Parkinson’s disease. Brain. 2018;141(2):505–520. doi:10.1093/brain/awx351
   Web of Science ®Google Scholar
• Longhena F, Faustini G, Missale C, Pizzi M, Bellucci A. Dopamine transporter/ alpha-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: an in situ proximity ligation assay study. Int J Mol Sci. 2018;19(6):19. doi:10.3390/ijms19061611
   Web of Science ®Google Scholar
• Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol. 2013;20(1):102–108. doi:10.1111/j.1468-1331.2012.03798.x
   PubMed Web of Science ®Google Scholar
• Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791–804. doi:10.1124/jpet.102.039867
   PubMed Web of Science ®Google Scholar
• Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson’s disease: a review of the literature. Clin Ther. 2006;28(1):1–12. doi:10.1016/j.clinthera.2005.12.003
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002;59(3):408–413. doi:10.1212/WNL.59.3.408
   PubMed Web of Science ®Google Scholar
• Witjas T, Eusebio A, Fluchere F, Azulay JP. Addictive behaviors and Parkinson’s disease. Rev Neurol (Paris). 2012;168(8–9):624–633. doi:10.1016/j.neurol.2012.06.014
   Web of Science ®Google Scholar
• Müller T, Öhm G, Eilert K, et al. Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease. J Neural Transm (Vienna). 2017;124(6):715–720. doi:10.1007/s00702-017-1701-3
   PubMed Web of Science ®Google Scholar
• de Chazeron I, Durif F, Chereau-Boudet I, et al. Compulsive eating behaviors in Parkinson’s disease. Eat Weight Disord. 2019;24(3):421–429. doi:10.1007/s40519-019-00648-1
   Web of Science ®Google Scholar
• Delpont B, Lhommee E, Klinger H, et al. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson’s disease. Mov Disord. 2017;32(11):1566–1573. doi:10.1002/mds.27101
   Web of Science ®Google Scholar
• Martini A, Dal LD, Edelstyn NMJ, Salgarello M, Lugoboni F, Tamburin S. Dopaminergic neurotransmission in patients with Parkinson’s disease and impulse control disorders: a systematic review and meta-analysis of PET and SPECT studies. Front Neurol. 2018;9:1018. doi:10.3389/fneur.2018.01018
   PubMed Web of Science ®Google Scholar
• Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol. 1980;8(6):558–563. doi:10.1002/ana.410080603
   PubMed Web of Science ®Google Scholar
• Margolesky J, Singer C. Extended-release oral capsule of carbidopa-levodopa in Parkinson disease. Ther Adv Neurol Disord. 2018;11:1756285617737728. doi:10.1177/1756285617737728
   Web of Science ®Google Scholar
• Nausieda PA, Hsu A, Elmer L, et al. Conversion to IPX066 from standard levodopa formulations in advanced Parkinson’s disease: experience in clinical trials. J Parkinsons Dis. 2015;5(4):837–845. doi:10.3233/JPD-150622
   Google Scholar
• Calabrese V, Di MA, Marino G, et al. Rapamycin, by inhibiting mTORC1 signaling, prevents the loss of striatal bidirectional synaptic plasticity in a rat model of L-DOPA-induced dyskinesia. Front Aging Neurosci. 2020;12:230. doi:10.3389/fnagi.2020.00230
   Web of Science ®Google Scholar
• Eshraghi M, Ramirez-Jarquin UN, Shahani N, et al. RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson’s disease. Sci Adv. 2020;6:eaaz7001. doi:10.1126/sciadv.aaz7001
   Web of Science ®Google Scholar
• Guttler C, Altschuler J, Tanev K, et al. Levodopa-induced dyskinesia are mediated by cortical gamma oscillations in experimental parkinsonism. Mov Disord. 2020. doi:10.1002/mds.28403
   PubMed Web of Science ®Google Scholar
• Costa C, Sgobio C, Siliquini S, et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease. Brain. 2012;135(6):1884–1899. doi:10.1093/brain/aws101
   PubMed Web of Science ®Google Scholar
• Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012;45(3):939–953. doi:10.1016/j.nbd.2011.12.013
   PubMed Web of Science ®Google Scholar
• Durante V, de Iure A, Loffredo V. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain. 2019;142(5):1365–1385. doi:10.1093/brain/awz065
   Web of Science ®Google Scholar
• Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol. 2002;451(2):157–160. doi:10.1016/S0014-2999(02)02268-9
   PubMed Web of Science ®Google Scholar
• Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord. 2002;17(5):877–886. doi:10.1002/mds.10238
   Web of Science ®Google Scholar
• Frackiewicz EJ, Jhee SS, Shiovitz TM, et al. Brasofensine treatment for Parkinson’s disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002;36(2):225–230. doi:10.1345/aph.1A152
   Web of Science ®Google Scholar
• Yu P. Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000;1:504–507.
   Google Scholar
• Cheng WC, Liu CM, Hsieh MH, Hwang TJ. Bupropion-related parkinsonism and dystonia. J Clin Psychopharmacol. 2009;29(6):616–618. doi:10.1097/JCP.0b013e3181c07a3f
   Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology. 1984;34(8):1092–1094. doi:10.1212/WNL.34.8.1092
   PubMed Web of Science ®Google Scholar
• Vegda M, Panda S. Bupropion-induced dystonia in a patient with parkinson’s disease. J Mov Disord. 2020;13(3):241–243. doi:10.14802/jmd.20046
   Web of Science ®Google Scholar
• Benincasa D, Pellicano C, Fanciulli A, Pontieri FE. Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson’s disease. Mov Disord. 2011;26(2):355–357. doi:10.1002/mds.23395
   Web of Science ®Google Scholar
• Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson’s disease and it’s various treatments. Med Hypotheses. 2010;75(6):544–546. doi:10.1016/j.mehy.2010.07.024
   PubMed Web of Science ®Google Scholar
• Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson’s disease. Int Psychogeriatr. 2011;23(2):325–327. doi:10.1017/S1041610210001687
   PubMed Web of Science ®Google Scholar
• Bedard P, Parkes JD, Marsden CD. Nomifensine in Parkinson’s disease. Br J Clin Pharmacol. 1977;4(Suppl 2):187S–190S. doi:10.1111/j.1365-2125.1977.tb05751.x
   Web of Science ®Google Scholar
• Park DM, Findley LJ, Teychenne PF. Nomifensine in parkinsonism. Br J Clin Pharmacol. 1977;4(Suppl 2):185S–186S. doi:10.1111/j.1365-2125.1977.tb05750.x
   Web of Science ®Google Scholar
• Park DM, Findley LJ, Hanks G, Sandler M. Nomifensine: effect in Parkinsonian patients not receiving levodopa. J Neurol Neurosurg Psychiatry. 1981;44(4):352–354. doi:10.1136/jnnp.44.4.352
   Web of Science ®Google Scholar
• Teychenne PF, Park DM, Findley LJ, Rose FC, Calne DB. Nomifensine in parkinsonism. J Neurol Neurosurg Psychiatry. 1976;39(12):1219–1221. doi:10.1136/jnnp.39.12.1219
   Web of Science ®Google Scholar
• Kapur A. Is methylphenidate beneficial and safe in pharmacological cognitive enhancement? CNS Drugs. 2020;34:1045–1062.
   Web of Science ®Google Scholar
• Lou JS. Fatigue in Parkinson’s disease and potential interventions. NeuroRehabilitation. 2015;37(1):25–34. doi:10.3233/NRE-151238
   Web of Science ®Google Scholar
• Nutt JG, Carter JH, Carlson NE. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch Neurol. 2007;64(3):319–323. doi:10.1001/archneur.64.3.319
   PubMedGoogle Scholar
• Shen Y, Huang JY, Li J, Liu CF. Excessive daytime sleepiness in parkinson’s disease: clinical implications and management. Chin Med J (Engl). 2018;131(8):974–981. doi:10.4103/0366-6999.229889
   Web of Science ®Google Scholar
• Huot P, Johnston TH, Gandy MN, et al. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. PLoS One. 2012;7(9):e45587. doi:10.1371/journal.pone.0045587
   Web of Science ®Google Scholar
• Huot P, Johnston TH, Lewis KD, et al. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. 2014;82:76–87. doi:10.1016/j.neuropharm.2014.01.012
   PubMed Web of Science ®Google Scholar
• Johnston TH, Millar Z, Huot P, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates. FASEB J. 2012;26(5):2154–2163. doi:10.1096/fj.11-195016
   Web of Science ®Google Scholar
• Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease. Mov Disord. 2007;22(3):359–365. doi:10.1002/mds.21258
   PubMed Web of Science ®Google Scholar
• Rascol O, Poewe W, Lees A, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol. 2008;65(5):577–583. doi:10.1001/archneur.65.5.577
   Google Scholar
• Huot P, Fox SH, Brotchie JM. Dopamine reuptake inhibitors in parkinson’s disease: a review of nonhuman primate studies and clinical trials. J Pharmacol Exp Ther. 2016;357(3):562–569. doi:10.1124/jpet.116.232371
   Web of Science ®Google Scholar
• Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev. 2006;30:1–23.
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999;19(4):329–335. doi:10.1097/00004714-199908000-00008
   PubMed Web of Science ®Google Scholar
• Moreau JL, Borgulya J, Jenck F, Martin JR. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol. 1994;5(3):344–350. doi:10.1097/00008877-199406000-00012
   PubMed Web of Science ®Google Scholar
• Apud JA, Weinberger DR. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs. 2007;21(7):535–557. doi:10.2165/00023210-200721070-00002
   Web of Science ®Google Scholar
• Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007;32(5):1011–1020. doi:10.1038/sj.npp.1301227
   Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 2007;22(4):329–335.
   Web of Science ®Google Scholar
• Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson’s disease patients. Tolcapone De novo study group. Mov Disord. 1998;13(4):643–647. doi:10.1002/mds.870130406
   PubMed Web of Science ®Google Scholar
• Männisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51(4):593–628.
   PubMed Web of Science ®Google Scholar
• Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174. doi:10.1007/s40265-014-0343-0
   PubMed Web of Science ®Google Scholar
• Müller T, Kuhn W, Möhr JD. Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia. Expert Opin Pharmacother. 2019;20(10):1181–1187. doi:10.1080/14656566.2019.1612365
   PubMed Web of Science ®Google Scholar
• Rinne UK. Treatment of early Parkinson’s disease. Parkinsonism Relat Disord. 2000;7(1):59–62. doi:10.1016/S1353-8020(00)00040-7
   Web of Science ®Google Scholar
• Silver DE, Ruggieri S. Initiating therapy for Parkinson’s disease. Neurology. 1998;50:S18–S22. doi:10.1212/WNL.50.6_Suppl_6.S18
   Web of Science ®Google Scholar
• Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252(Suppl 4):IV37–IV42. doi:10.1007/s00415-005-4008-5
   PubMed Web of Science ®Google Scholar
• Hinz M, Stein A, Cole T. The Parkinson’s disease death rate: carbidopa and vitamin B6. Clin Pharmacol. 2014;6:161–169. doi:10.2147/CPAA.S70707
   PubMedGoogle Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13:707–718. doi:10.1586/ern.13.50
   PubMed Web of Science ®Google Scholar
• Müller T, Trommer I, Muhlack S, Mueller BK. Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm (Vienna). 2016;123(4):401–406. doi:10.1007/s00702-016-1519-4
   PubMed Web of Science ®Google Scholar
• Leal RM, Rascol O, Ferreira JJ. The “long and winding road” of the disease-modifying effects of levodopa has not ended yet. Mov Disord. 2020;35(3):397–399. doi:10.1002/mds.27961
   Web of Science ®Google Scholar
• Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med. 2019;380(4):315–324. doi:10.1056/NEJMoa1809983
   PubMed Web of Science ®Google Scholar
• Rma DB, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 2020;19(5):452–461. doi:10.1016/S1474-4422(20)30036-3
   PubMed Web of Science ®Google Scholar
• Müller T. Entacapone. Expert Opin Drug Metab Toxicol. 2010;6(983–993):983–993. doi:10.1517/17425255.2010.502167
   Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27. doi:10.1002/ana.22060
   PubMed Web of Science ®Google Scholar
• Warren OC, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–1071. doi:10.1002/mds.25364
   Web of Science ®Google Scholar
• Levein NG, Thorn SE, Wattwil M. Dopamine delays gastric emptying and prolongs orocaecal transit time in volunteers. Eur J Anaesthesiol. 1999;16(4):246–250. doi:10.1097/00003643-199904000-00006
   PubMed Web of Science ®Google Scholar
• Barone JA. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–440. doi:10.1345/aph.18003
   PubMed Web of Science ®Google Scholar
• Shuto K, Shiozaki Z, Kojima T, Tanaka M. Antagonism of KW-5338 (domperidone) against emesis and depression of intestinal motility induced by L-DOPA. J Pharmacobiodyn. 1980;3(12):709–714. doi:10.1248/bpb1978.3.709
   Google Scholar
• Koprdova R, Csatlosova K, Durisova B, et al. Electrophysiology and behavioral assessment of the new molecule SMe1EC2M3 as a representative of the future class of triple reuptake inhibitors. Molecules. 2019;24(23):24. doi:10.3390/molecules24234218
   Web of Science ®Google Scholar
• Chu Y, Muller S, Tavares A, et al. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019;142(11):3565–3579. doi:10.1093/brain/awz296
   Web of Science ®Google Scholar
• Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12(8):747–755. doi:10.1016/S1474-4422(13)70117-0
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101. doi:10.1002/ana.10609
   PubMed Web of Science ®Google Scholar
• Bellucci A, Navarria L, Falarti E, et al. Redistribution of DAT/alpha-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease. PLoS One. 2011;6(12):e27959. doi:10.1371/journal.pone.0027959
   Web of Science ®Google Scholar
• Chadchankar H, Ihalainen J, Tanila H, Yavich L. Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res. 2011;1382:37–44. doi:10.1016/j.brainres.2011.01.064
   Web of Science ®Google Scholar
• Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001;15(6):916–926. doi:10.1096/fj.00-0334com
   Web of Science ®Google Scholar
• Wersinger C, Prou D, Vernier P, Sidhu A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 2003;17(14):2151–2153. doi:10.1096/fj.03-0152fje
   Web of Science ®Google Scholar
• Bellucci A, Collo G, Sarnico I, Battistin L, Missale C, Spano P. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2D3 receptor activation. J Neurochem. 2008;106(2):560–577. doi:10.1111/j.1471-4159.2008.05406.x
   Web of Science ®Google Scholar
• Faustini G, Longhena F, Varanita T, et al. Synapsin III deficiency hampers alpha-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease. Acta Neuropathol. 2018;136(4):621–639. doi:10.1007/s00401-018-1892-1
   PubMed Web of Science ®Google Scholar
• Faustini G, Longhena F, Bruno A, et al. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. Neurobiol Dis. 2020;138:104789. doi:10.1016/j.nbd.2020.104789
   Web of Science ®Google Scholar